SRP4978

Sigma-Aldrich

IL-28 human

recombinant, expressed in E. coli, ≥85% (SDS-PAGE), ≥85% (HPLC)

Sinónimos:
IFN-λ 2, Interleukin-28A, IL28A, Cytokine ZCYTO20, Interferon-λ 2
MDL number:
NACRES:
NA.32
En este momento no podemos mostrarle ni los precios ni la disponibilidad

biological source

human

recombinant

expressed in E. coli

assay

≥85% (HPLC)
≥85% (SDS-PAGE)

form

lyophilized

mol wt

~19.6 kDa

packaging

pkg of 20 μg

impurities

endotoxin, tested

NCBI accession no.

shipped in

wet ice

storage temp.

−20°C

Gene Information

human ... IL28(282616)

General description

IL-28 (interleukin 28), or IFNL2 (interferon λ2), belongs to the novel IFN type III family, which contains IL-29 and IL-28A and IL-28B. IL-28A and IL-28B share >95% sequence identity. This gene is localized to human chromosome 19.
Recombinant human IL-28A produced in Escherichia coli is a single, non-glycosylated, polypeptide chain containing 175 amino acids and having a molecular mass of 19.6kDa.

Biochem/physiol Actions

IL-28A (interleukin 28) can inhibit multiple types of virus, and is also capable of preventing HSV-1 (herpes simplex virus type 1) infection of human neuronal cells. The antiviral property of IL-28A is attributable to IL-28A being capable of activating the expression of various Toll-like receptors (TLRs) and stimulating the TLR-mediated antiviral pathway, such as IFN regulatory factor 7, IFN-α, and the central IFN-α stimulated antiviral genes. IL-28A also acts as an inhibitory factor in HCV (hepatitis C virus) replication, and its expression is increased in HCV patients. This HCV antiviral activity is the result of IL-28A activating JAK-STAT (Janus kinase-signal transducer and activator of transcription) signaling pathway and the activation of certain interferon-stimulated genes (ISGs), such as 6-16 and 1-8U. Therefore, it might have potential as a therapeutic target in the treatment of HCV.

Physical form

Lyophilized without additives.

Reconstitution

Reconstitute in sterile dH2O not less than 100 μg/ml. This solution can then be diluted into other aqueous buffers.
Centrifuge the vial prior to opening. Avoid freeze-thaw cycles.
Certificado de Análisis
IL-29/IL-28A suppress HSV-1 infection of human NT2-N neurons.
Zhou L et al
Journal of Neurovirology, 17(3), 212-219 (2011)
Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus.
Diegelmann J et al
PLoS ONE, 5(12), e15200-e15200 (2010)
Sequence analysis of the IL28A/IL28B inverted gene duplication that contains polymorphisms associated with treatment response in hepatitis C patients.
Reynolds JM et al
PLoS ONE, 7(1), e29983-e29983 (2012)
Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication.
Zhu H et al
Virology Journal, 2, 80-80 (2005)

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.